By Ben Glickman
Shares of Caribou Biosciences rose after the company's lymphoma trial design was approved by the Food and Drug Administration.
The stock was up 4.1% to $5.88 in after-hours trading following a 1.9% drop at Tuesday's close. Shares are down 10% this year.
The Berkeley, Calif.-based gene-editing pharmaceutical company said it had received feedback from the FDA on its Phase 3 trial for CB-010, a treatment for large B cell lymphoma.
The company plans to initiate its Phase 3 trial by the end of 2024.
The trial design includes platinum-based immunochemotherapy, followed by high-dose chemotherapy and autologous stem cell transplantation.
Chief Executive Rachel Haurwitz said the FDA feedback was "an important step in advancing our lead therapy."
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
12-12-23 1811ET